Indian media is claiming that India is close to introducing its first locally developed vaccine for the prevention of dengue.
According to Indian media, the vaccine named DengiAll is currently in the final stage of Phase Three clinical trials. It has been developed by pharmaceutical company Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR).
Indian media claims that the vaccine has been designed to provide protection against all four serotypes of the dengue virus.
A key feature of this vaccine is that it consists of only a single dose, whereas most existing vaccines around the world require multiple doses.
